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Abstract
Caveolae are plasma membrane structures formed from a complex of the proteins caveolin-1 and caveolin-2. Caveolae
interact with pro-inflammatory cytokines and are dysregulated in fibrotic disease. Although caveolae are present
infrequently in healthy kidneys, they are abundant during kidney injury. An association has been identified between a CAV1
gene variant and long term kidney transplant survival. Chronic, gradual decline in transplant function is a persistent
problem in kidney transplantation. The aetiology of this is diverse but fibrosis within the transplanted organ is the common
end point. This study is the first to investigate the association of CAV2 gene variants with kidney transplant outcomes.
Genomic DNA from donors and recipients of 575 kidney transplants performed in Belfast was investigated for common
variation in CAV2 using a tag SNP approach. The CAV2 SNP rs13221869 was nominally significant for kidney transplant
failure. Validation was sought in an independent group of kidney transplant donors and recipients from Dublin, Ireland
using a second genotyping technology. Due to the unexpected absence of rs13221869 from this cohort, the CAV2 gene was
resequenced. One novel SNP and a novel insertion/deletion in CAV2 were identified; rs13221869 is located in a repetitive
region and was not a true variant in resequenced populations. CAV2 is a plausible candidate gene for association with
kidney transplant outcomes given its proximity to CAV1 and its role in attenuating fibrosis. This study does not support an
association between CAV2 variation and kidney transplant survival. Further analysis of CAV2 should be undertaken with an
awareness of the sequence complexities and genetic variants highlighted by this study.
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Introduction
Transplantation is the optimum treatment for end-stage kidney
disease (ESKD). A kidney transplant improves the quality of life
and survival of the recipient and substantially reduces the cost of
ESKD to the healthcare provider [1,2]. One year transplant
survival rates following kidney transplantation have improved
substantially in the last two decades; death censored transplant loss
within the first 12 months has decreased from 15.7% in 1989 to
4% in 2008 [3]. However, the improvements in longer term
kidney transplant survival have been less impressive [3,4]. Chronic
and gradual loss of kidney transplant function is due to myriad
immunological and non-immunological insults. These include
chronic antibody mediated rejection, calcineurin inhibitor toxicity,
recurrent infection, urinary tract obstruction, hypertension and de
novo or recurrent glomerular disease [5–7]. The cumulative injury
to the transplant causes vascular and glomerular remodelling,
extracellular matrix expansion, tubular atrophy and fibrogenesis
[5,7,8]. Widespread fibrosis of the transplanted kidney is the final
common endpoint [6].
Caveolae are flask-shaped, plasmalemmal invaginations formed
from a stable hetero-oligomeric complex of the proteins caveolin 1
(CAV1) and caveolin 2 (CAV2) combined with cholesterol and
sphingolipid rich molecules [9,10]. Caveolae facilitate protein
transcytosis, ion channel regulation, cholesterol transport and
endocytosis of toxins, viruses and signalling molecules. These
intricate structures are present in many cell types but are most
abundant in adipocytes, endothelial cells, type 1 pneumocytes,
myocytes, and fibroblasts [11].
Interaction exists between the caveolin binding domains and the
high concentrations of signal transduction proteins contained
within caveolae. Caveolar endocytosis and degradation of these
proteins result in down-regulation of the signalling cascade
[11,12]. Transforming growth factor beta (TGFb) is a pro-fibrotic
cytokine which plays a key role in the initiation and propagation of
fibrosis within the kidney [13]. The generation of pro-fibrotic
proteins is up regulated by TGFb with simultaneous loss of cell
adhesion molecules leading to aberrant cell migration and
compromise of the tubular basement membrane coupled with
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fibroblast proliferation and invasion [13]. Myofibroblasts differ-
entiate from resident interstitial fibroblasts under TGFb stimula-
tion and TGFb promotes calcineurin inhibitor-induced kidney
transplant fibrosis [13,14]. TGFb receptors are contiguous with
and located within caveolae; TGFb is down regulated by caveolar
endocytosis of this signalling molecule [12,15]. CAV1 further
suppresses TGFb by interacting with the inhibitory Smad pathway
causing TGFb receptor degradation [9,16]. CAV1 is recognised as
an inhibitor of both cell proliferation and fibrosis and is known to
be dysregulated in fibrotic diseases such as systemic sclerosis,
pulmonary fibrosis, fibrosing cardiomyopathy, and keloid forma-
tion [15,17,18].
Healthy glomerular and peritubular capillary endothelial cells
have few caveolae [19,20]. However, in chronic antibody
mediated rejection, substantial numbers of caveolae are found in
endothelial cells and the degree of CAV1 expression correlates with
the pathological severity of rejection (graded by the Banff Score)
[20,21]. There is also abundant production of CAV1 in the
glomerular endothelium of patients with glomerulonephritis [19].
In animal models of tubulointerstitial scarring, reduced CAV1
expression is associated with increased tubulointerstitial injury and
fibrosis [22,23]. An association has recently been identified
between a CAV1 gene variant and kidney transplant survival.
The donor CAV1 single nucleotide polymorphism (SNP)
rs4730751 is significantly associated with transplant failure and
an increased incidence of transplant fibrosis [15]. In a replication
cohort, this association with kidney transplant failure was
demonstrated with both the donor and recipient CAV1 SNPs [15].
In contrast to CAV1, little is known about the function of CAV2
although it has been implicated in type 2 diabetes mellitus [24],
systemic sclerosis [18], cardiac conduction defects [25], cancer
[26,27], and primary open angle glaucoma [28]. Its role in the
development of fibrosis has not been established. The CAV2 gene
is adjacent to the CAV1 locus at 7q31.1 and is a plausible
candidate gene for association with kidney transplant survival.
This study is the first to investigate the association between
CAV2 gene variants and kidney transplant outcomes. The primary
end-point was death-censored transplant failure. Variants in the
CAV2 gene were genotyped for both donors and recipients of first
deceased donor kidney transplants with validation sought in an
independent cohort of kidney transplant donors and recipients
from Dublin, Ireland. Both donor and recipient genomes may
affect transplant outcomes since cells from each are implicated in
vascular and glomerular remodelling during chronic transplant
injury [29–31].
Materials and Methods
Ethics Statement
Ethical approval was granted for this study by the Office for
Research Ethics Committees Northern Ireland (http://www.
orecni.org.uk, 08/NIR3/79). Clinical follow up data has been
stored in a regional transplant database since 1969. Written
consent is obtained prospectively from recipients, or their
guardians in the case of minors, for the storage of this data.
However, written consent was not obtained from all recipients
prior to 2006. The regional ethics committee waived the
Figure 1. Haploview plot showing linkage disequilibrium between original tag SNPs downloaded from the International HapMap
Project (release 28).
doi:10.1371/journal.pone.0063358.g001
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requirement for written consent from these recipients and granted
permission for all of this data to be used in research involving the
corresponding transplant DNA samples. All kidney transplant
recipient and kidney donor data is fully anonymised by the clinical
team prior to analysis. It is not possible for researchers to identify
recipients from the data.
Patient cohort
The Regional Nephrology Unit at Belfast City Hospital, Belfast
is the only kidney transplant centre in Northern Ireland. Since
1986, genomic DNA has been obtained and stored from all
recipient-donor pairs in first deceased donor kidney transplants at
this centre.
There were 707 first, deceased donor transplants between May
1986 and April 2005. DNA was available for genotyping from 575
recipient-donor pairs. Clinical data and outcomes were recorded
prospectively for all transplant recipients. Over 99% of both
populations were White. Transplant failure is defined as a move to
an alternative renal replacement modality such as dialysis therapy
(death-censored transplant failure).
Single Nucleotide Polymorphism selection for CAV2
Genotype data for SNPs across the CAV2 gene, including 5 kb
flanking the CAV2 59 and 39 untranslated regions, was downloaded
from the International HapMap Project [32], release 28 (http://
hapmap.ncbi.nlm.nih.gov), for the CEPH population (Utah
residents with ancestry from northern and western Europe).
Information was available for 36 SNPs, of which 13 met the
criteria of a minor allele frequency (MAF) .5%, Hardy Weinberg
equilibrium . 0.001 and successful genotyping rate .95%. All
SNPs had a MAF of at least 10%. Haploview [33] (version 4.2,
www.broadinstitute.org/haploview) was used to identify linkage
disequilibrium between SNPs and visualise haplotype blocks
(Figure 1); seven tag SNPs were selected using a pairwise approach
where r2.0.8. These seven tag SNPs {rs10258482, rs17138767,
rs10253097, rs2109513, rs4730743, rs17138755 and rs11980719}
are sufficient to examine all recorded common variation across the
genetic region encompassing the CAV2 gene.
The Ensembl Genome Browser (www.ensembl.org) was
searched for putatively functional SNPs in CAV2; a further three
non-synonymous SNPs for CAV2 {rs13234554, rs13221869 and
rs8940} were identified.
Genotyping
Eight SNPs were genotyped using Sequenom iPLEX technology
(Sequenom, Hamburg, Germany) and two using Taqman
technology (Applied Biosystems, Warrington, Cheshire, UK).
Recipient and donor DNA samples were randomly arranged in
a 384-well format with four father-mother-proband trios and four
negative controls per plate. The full details of primers, reaction
conditions, equipment and software utilised are available from the
authors.
Power Calculation
Statistical power was calculated using StatCalc (version 6). This
discovery cohort has .80% power to identify a risk allele of
OR$1.5 at the 5% significance level, assuming a MAF of 10%.
Replication
SNPs that showed nominal association between SNP and
transplant survival in the discovery cohort were genotyped in an
independent cohort of 144 kidney transplant recipient-donor pairs
from Beaumont Hospital, Dublin, Ireland. These donor and Figure 2. Schematic diagram of CAV2.
doi:10.1371/journal.pone.0063358.g002
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recipient cohorts are comparable to the Belfast populations in
terms of ethnicity, age and primary kidney disease. Taqman
technology was used for replication genotyping.
Direct Capillary Sequencing
The CAV2 reference sequence (homo sapiens chr7
(GRCh37:115924434...116151595)) was obtained from GenBank
at the National Center for Biotechnology Information (www.ncbi.
nlm.nih.gov/genbank/). The genomic region of interest was
extended to 4.5 kb upstream from the reference mRNA
transcription start site and 6 kb downstream from the stop codon
to also investigate functional regions that may influence expression
of CAV2. Twenty-six overlapping fragments were PCR amplified
using genomic DNA from 31 individuals. The average fragment
length was 692 base pairs. Bidirectional sequencing was
undertaken using Genetic Analyser 3730 (Applied Biosystems,
Warrington, UK) and sequencing conditions are available from
the authors. Contigs were mapped to the reference genome and
visualised using Vector NTI (Invitrogen Ltd, Paisley, UK)
(Figure 2). Haploview [33] was used to identify linkage
disequilibrium between SNPs and visualise haplotype blocks
(Figure 3).
Statistical Analysis
Genotype distributions for recipient and donor groups were
assessed for Hardy-Weinberg equilibrium. Cumulative transplant
and recipient survival were analysed using Kaplan-Meier survival
plots with the log rank test assessing inter-group variation.
There are a number of clinical features including donor age,
recipient age, recipient gender, diabetic nephropathy, acute
rejection, decade of transplantation, ischemic time and degree of
HLA mismatching which are generally accepted to impact
transplant and/or recipient survival. There were also significant
improvements in transplantation during this period. To allow for
this in the analysis, each transplant was coded according to the
decade of transplantation; decade one encompassed transplants
performed between 1986 and 1995 and decade two, those
performed between 1996 and 2005 inclusive. Log rank testing
was used to assess the impact of these variables on transplant
outcome. A Cox proportional-hazards model was used to perform
multiple regression analysis incorporating variables which impact
transplant survival.
Genotype and allelic group comparisons were made using the
Chi-squared test.
A p value of ,0.05 was considered nominally statistically
significant in all analyses. SPSS for Windows (SPSSH Inc.,
Chicago, Illinois) version 17.0 was used for all analyses.
Results
Clinical
There were 707 first deceased donor kidney transplants during
the period studied. The average age of recipients was 42 years
(range 2–77 years) and the average age of kidney donors was 37
years (range 1–75 years). 439 (62.1%) of recipients and 428
(60.5%) of donors were male (Table 1).
The median follow up time in this study was 12.2 years (range
0–26.0 years). There were 438 transplant failures: 187 recipients
died with a functioning transplant and 251 transferred to an
alternative mode of renal replacement therapy. There were 105
deaths in the latter group within the follow up period.
Donor age (p,0.001), acute rejection within 6 months
(p,0.001) and earlier decade of transplantation (p = 0.026) were
significantly associated with transplant failure. Recipient age
(p,0.001), donor age (p = 0.002), diabetic nephropathy as the
primary renal diagnosis (p,0.001), and earlier decade of
Figure 3. Haploview plot showing linkage disequilibrium between CAV2 SNPs using resequencing data.
doi:10.1371/journal.pone.0063358.g003
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transplantation (p= 0.005) were significantly associated with
recipient mortality. For the purpose of this analysis, donor and
recipient age were grouped into decades. The degree of HLA
mismatching across A, B and DR loci did not significantly
influence transplant outcomes. As has previously been described,
this probably reflects the policy of favourable matching at this
centre. Only 1% of this cohort had two mismatches at the DR
locus [34,35].
Genotyping
The average genotyping success rate was 93%. Genotypes for
SNP rs4730743 and rs10258482 deviated from Hardy-Weinberg
Equilibrium in both recipients and controls and were therefore
excluded from further analysis. SNP rs13234554 was also excluded
due to unreliable genotype calls. Recipient genotyping data and
associations with transplant survival are shown in Table 2. There
was no association between donor variability and transplant
outcomes. Using Kaplan-Meier survival analysis, significant
associations were identified between transplant survival and
recipient variants at the tag SNP rs11980719 (p = 0.024). The
most significant association with a non-synonymous SNP was with
recipient rs13221869 (p = 0.085). The presence of a T allele was
protective for rs11980719 and the presence of a C allele was
associated with transplant survival benefit for rs13221869
(Figure 4). There were no donors or recipients who were
homozygous for a C allele at rs13221869. Analysis revealed that
rs11980719 and rs13221869 are not in strong linkage disequilib-
rium (r2 0.635).
There was no significant association between rs11980719
(p = 0.375) or rs13221869 (p = 0.926) and biopsy proven acute
rejection within the first 6 months of transplantation. Insufficient
transplant biopsy results are available to identify any correlation
between CAV2 SNPs and a specific aetiology of chronic transplant
failure. There was no significant association between these SNPs
and recipient survival.
A Cox regression-proportional hazards model was used to
correct for variables which were significantly associated with
transplant survival in our population (donor age, acute rejection
within 6 months and decade of transplantation) as well as those
which are generally accepted to impact transplant survival but that
did not reach statistical significance in this cohort (recipient
gender, recipient age, degree of HLA mismatching, ischemic time).
In this analysis, the association between rs13221869 and
transplant survival was magnified (HR 0.422, CI 0.173–1.031,
p = 0.058) (Table 3) but this was not the case with rs11980719 (HR
1.295, CI 0.872–1.922, p = 0.20).
Replication
When rs13221869 was genotyped in the replication cohort, the
SNP was unexpectedly reported as monomorphic. A second set of
Taqman primers and probes were designed but genotyping once
again detected a single allele at this locus. The Belfast and Dublin
transplant populations are genetically similar and the failure to
identify rs13221869 in this population was surprising. This, along
with the unusually high proportion of SNPs that failed quality
control, led us to resequence this potentially important biological
and positional candidate gene.
Direct Capillary Sequencing
17 kb surrounding the CAV2 gene was bi-directionally
resequenced. There were 181 unique SNPs reported in the
CAV2 gene; 60 of these were confirmed in our population (Table 4,
Figure 2). Six of these known variations deviated from Hardy
Weinberg equilibrium in the resequencing study; the SNPs
rs55994026, rs67933359, rs2024209 and rs13229461 and two
insertion/deletions rs35459680 and rs72194526. In addition, one
novel insertion/deletion (base position 9170, GAGG/-,
ss550827879) and one novel SNP (base position 15927, A/T,
ss550827880) were identified. Linkage disequilibrium between the
SNPs and haplotype blocks is shown in Figure 3.
The primers initially designed to screen fragment 8 (750bp,
Figure 2), which included rs13221869, failed at sequencing. Two
further sets of sequencing primers were designed and a nested
PCR was required to optimise the sequence data for this
technically challenging region. Six individuals who were clearly
heterozygous (T/C) for rs13221869 by Sequenom and two
homozygotes (T/T) were resequenced. None of the reported
SNPs in this region (variation 2051–2055) were present in our
resequencing dataset. In samples which had been reported as
rs13221869 (Variation 2054) heterozygotes using Sequenom, there
was no evidence of single nucleotide variation at this locus.
Detailed review of the failed sequencing data suggested that the
initial sequenced DNA strands were misaligned by three bases.
This led to the appearance of SNPs in reasonable sequencing
chromatograms that were not present when the region was
‘correctly’ aligned using a long, clean sequencing read. Despite
BLAST analysis at the Sequenom primer design stage and good
predicted quality scores, there are multiple loci in the annealing
sequence of the Sequenom unextended primer where a short
identical sequence is repeated three bases upstream.
Table 1. Clinical characteristics of Belfast Kidney Transplant
Population.
Variable n
Recipient age/years
Mean (SD) 42 (16.7)
Recipient gender
Male 439 (62%)
Donor age/years
Mean (SD) 37 (16.8)
Donor gender
Male 428 (61%)
Primary renal disease
Glomerulonephritis 139 (20%)
Intersitial/pyelonephritis 144 (20%)
Autosomal Dominant Polycystic Kidney Disease 103 (15%)
Diabetic nephropathy 71 (10%)
Other 157 (22%)
Unknown 93 (13%)
Decade of transplantation
1986–1995 380 (54%)
1996–2005 327 (46%)
HLA mismatch/number of mismatches
Mean (SD) 2.2 (1.1)
Ischaemic time/minutes
Mean (SD) 1428 (440)
Acute rejection* 143 (20%)
*Biopsy proven within 6 months of transplant
doi:10.1371/journal.pone.0063358.t001
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Discussion
Improving long term outcomes in kidney transplantation
remains a challenge. Transplant failure within the first year has
been reduced by the development of new immunosuppressive
drugs and advanced surgical techniques and a lasting survival
benefit was expected [7,30,36]. The reality has been disappoint-
ing. While the rate of transplant loss within five years has
significantly improved in the modern era, the long term attrition
rate has remained largely unchanged [3,4,37].
This study follows the report of a risk variant in the CAV1 gene
that associates with poor transplant survival [15] and is the first to
investigate the effect of variation in the CAV2 gene on kidney
transplant outcomes. SNPs at the CAV2 locus were investigated
and a trend towards association was suggested between
rs13221869 in the recipient genome and transplant survival.
There was no association with recipient survival or acute rejection.
An attempt to replicate this association in an ethnically similar
kidney transplant recipient-donor population using an alternative
technology failed to genotype two alleles for this SNP.
Direct capillary sequencing was subsequently employed to
investigate the CAV2 gene in detail. Initial attempts to sequence
the fragment encompassing rs13221869 failed (base position 5039,
Pf8, Pr8, Figure 2) and an unusual degree of optimisation was
Figure 4. Kaplan-Maier plot showing association between recipient CAV2 SNP rs13221869 and transplant survival.
doi:10.1371/journal.pone.0063358.g004
Table 2. Genotype data and association with transplant
survival for CAV2 SNPs.
SNP Genotype Recipient p value Donor p value
8940 CC/CG/GG 369/132/15 0.831 378/165/21 0.608
10253097 TT/TC/CC 372/134/18 0.208 360/138/20 0.890
11980719 TT/TA/AA 237/241/72 0.024 216/270/73 0.998
13221869 TT/TC/CC 504/24/0 0.085 516/23/0 0.470
17138755 AA/AC/CC 439/99/8 0.326 440/101/7 0.558
17138767 AA/AG/GG 461/73/3 0.304 353/79/4 0.962
2109513 CC/CT/TT 410/143/11 0.097 402/169/13 0.663
doi:10.1371/journal.pone.0063358.t002
Table 3. Cox regression analysis of transplant survival.
Variable Hazard ratio
Confidence
Intervals p value
Donor age (per decade) 1.200 1.091–1.319 0.000
Decade of transplantation 0.772 0.564–1.057 0.107
Acute rejection u 2.015 1.469–2.765 0.000
Recipient gender 0.949 0.701–1.285 0.735
Recipient age (per decade) 0.854 0.776–0.939 0.001
HLA match 1.031 0.889–1.195 0.688
Ischaemic time (tertiles) 0.864 0.686–1.089 0.217
rs13221869 0.422 0.173–1.031 0.058
u Biopsy proven acute rejection within 6 months of transplant
doi:10.1371/journal.pone.0063358.t003
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Table 4. SNPs, insertions and deletions identified in CAV2 sequencing.
SNP Base position Base change Genotype Frequency MAF
rs2402080 183 G.C GG/GC/CC 14/11/6 0.371
rs62468983 290 G.A GG/GA/AA 25/6/0 0.097
rs17138755 355 A.C AA/AC/CC 25/6/0 0.097
rs17138756 420 A.G AA/AG/GG 24/6/1 0.129
rs2024209 503 T.C TT/TC/CC 27/0/3 0.100
rs6962355 859 G.A GG/GA/AA 23/7/0 0.117
rs35459680 1088 G.- GG/G-/-- 28/0/2 0.483
rs13223362 2173 G.A GG/GA/AA 11/12/6 0.414
rs6968230 2216 G.T GG/GT/TT 28/1/2 0.081
rs2402081 2462 C.T CC/CT/TT 1/6/23 0.129
rs13226307 2652 A.T AA/AT/TT 28/1/2 0.081
rs17138765 2693 G.A GG/GA/AA 29/2/0 0.032
rs17138767 2844 A.G AA/AG/GG 29/1/1 0.081
rs4730742 3059 T.G TT/TG/GG 18/10/3 0.258
rs77465210 3572 T.A TT/TA/AA 26/3/1 0.081
rs2191498 3736 C.T CC/CT/TT 27/1/2 0.083
rs12669740 3743 T.C TT/TC/CC 27/1/2 0.083
rs2191499 3766 C.T CC/CT/TT 27/1/2 0.083
rs2191500 3833 C.A CC/CA/AA 8/10/12 0.433
rs2191501 3998 G.T GG/GT/TT 13/1/1 0.048
rs2535220 5243 T.C TT/TC/CC 1/7/16 0.188
rs13235183 5316 G.T GG/GT/TT 22/1/1 0.062
rs11767363 5442 T.C TT/TC/CC 1/6/8 0.129
rs2270188 5691 G.T GG/GT/TT 14/11/5 0.350
rs2270189 5783 A.G AA/AG/GG 13/11/6 0.383
rs62468993 5931 G.A GG/GA/AA 27/3/0 0.050
rs28503222 6098 G.C GG/GC/CC 16/9/4 0.293
rs3779511 6945 T.G TT/TG/GG 9/16/6 0.452
rs76633992 6998 G.T GG/GT/TT 13/7/11 0.468
rs11980719 7975 T.A TT/TA/AA 9/16/4 0.414
rs62468996 8804 C.A CC/CA/AA 28/1/0 0.017
rs66557555 8823 G.- GG/G-/-- 27/2/0 0.048
rs10233003 8829 C.A CC/CA/AA 11/14/4 0.379
rs13229461 8969 C.T CC/CT/TT 23/3/5 0.293
rs67933359 9029 C.A CC/CA/AA 26/0/5 0.172
rs72194526 9117 Deletion GAGGGAGG/- 21/9 0.310
rs55994026 9132 G.A GG/GA/AA 23/0/8 0.241
ss550827879 9170 GAGG.- GAGG/- 30/1 0.016
rs10253097 10071 T.C TT/TC/CC 12/5/7 0.396
rs10271007 11016 A.G AA/AG/GG 10/10/5 0.400
rs75396674 11104 T.A TT/TA/AA 23/4/3 0.155
rs4730743 11124 A.T AA/AT/TT 13/11/5 0.362
rs8940* 11241 C.G CC/CG/GG 17/9/3 0.259
rs1055850* 11878 A.G AA/AG/GG 1/8/22 0.161
rs10249656* 12704 C.T CC/CT/TT 17/10/3 0.267
rs4727833* 13075 C.G CC/CG/GG 19/7/5 0.117
rs1052990* 13537 T.G TT/TG/GG 9/16/6 0.452
rs5886827* 13575 A.- AA/A-/-- 14/5/12 0.387
rs56213795 13711 G.A GG/GA/AA 29/2/0 0.016
Caveolin 2 Analysis and Kidney Transplantation
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required. This study highlights not only the need for validation of
interesting SNP associations using an alternative technology, but
also that future genetic studies of CAV2 in particular warrant
careful consideration. For example, our original Sequenom data
and 3730 sequencing showed a C/T variant at base position 5039,
which is the reported position of rs13221869. However, the use of
a longer sequencing fragment that reads through the difficult
region revealed this ‘SNP’ was due to misalignment of bases. This
SNP (rs13221869) was originally identified via large-scale
sequence comparisons and has not been confirmed by genotyping
or population frequency data (www.ncbi.nlm.nih.gov/projects/
SNP/snp_ref.cgi?rs = 13221869).
Repetitive DNA sequences account for 50–80% of the human
genome [38,39]. The repetition of DNA sequences causes
ambiguities in alignment and genome assembly in DNA sequenc-
ing and poses a significant problem. This is magnified by next
generation sequencing technologies as a result of the formation of
shorter DNA fragments where fewer bases are present to verify the
corresponding position in the reference genome [38]. Uniform
heterozygosity or excess heterozygosity resulting in Hardy
Weinberg disequilibrium may suggest that a SNP has been
identified as a result of sequence-read misalignment [40].
Misalignment of sequenced DNA resulted in the erroneous
identification of the heterozygote SNP rs13221869, which
appeared to be in Hardy Weinberg equilibrium when genotyped
using Sequenom in this study.
The steps necessary for the discovery of a new genetic variant
ought to be threefold: firstly, the detection of the variant (often by
large scale, high throughput approaches); secondly, the validation
of this finding in an independent population and thirdly,
characterization of the variant using an alternative technology
[41]. The National Center for Biotechnology Information CAV2
SNP genotype report lists 86 known SNPs in the CAV2 gene
(accessed 06.11.2012). Of these, only 20 have been confirmed by
population frequency or genotyping data, including two which
were confirmed in populations of less than five individuals. This
study identified six of the seven SNPs (rs8940, rs1052990,
rs1055850, rs4727833, rs5886827, rs10249656, rs56213795)
which have been validated in a population of European origin
with a MAF.5% and provides population frequency data for an
additional 54 SNPs. The Haploview plot of resequenced data
illustrates the paucity of linkage disequilibrium between the
confirmed SNPs (Figure 3). For this reason, it is not feasible to
accurately assess variation within the CAV2 gene using tag SNPs
derived from the existing version of the HapMap project (Figure 1).
At the turn of the millennium, the cost of sequencing the human
genome was $100,000,000 [42]. Today, the human genome may
be sequenced in its entirety for less than $1,000 [43]. This rapid
reduction in the cost of DNA sequencing and the exponential
increase in the output of sequencing platforms have resulted in an
unprecedented amount of information about the genetic code
becoming available. This, however, must be matched by accurate
and reproducible bioinformatics platforms for analysis and, even
more importantly, careful interpretation of the results. This
investigation of CAV2 illustrates the importance of replication
and detailed validation of findings in clinical genetic research.
Analysis of the human genome has provided useful insights into
the pathogenesis of chronic kidney disease and kidney transplant
outcomes [34,44–46]. These insights have resulted in advances
which are beginning to be translated into clinical practice [46].
CAV2 is a plausible candidate gene for association with kidney
transplant survival because of its proximity to the CAV1 locus and
its modulatory role in fibrosis and angiogenesis which are key
pathological components of chronic transplant dysfunction
[17,29]. The advantage of employing different technologies in
the investigation of CAV2 is emphasised by this study.
This study did not identify a significant association between
single nucleotide polymorphisms in CAV2 and kidney transplant
outcomes. However, it did identify novel variants, provide
frequency data for known variants and provide a plausible
explanation as to how a functional SNP might have been
mistakenly identified and reported.
Conclusion
This study is the first to investigate the role of recipient and
donor CAV2 variants in kidney transplant survival. There was no
association between genetic variation at CAV2 and either kidney
transplant or recipient survival. However, the resequencing data
identified novel SNPs, provided population data, and highlights
Table 4. Cont.
SNP Base position Base change Genotype Frequency MAF
rs10224685 14067 A.C AA/AC/CC 18/9/3 0.250
rs17515960 14743 A.G AA/AG/GG 25/6/0 0.097
rs62469000 15011 C.T CC/CT/TT 24/7/0 0.113
rs12536639 15012 G.A GG/GA/AA 18/10/3 0.258
rs55701446 15244 G.T GG/GT/TT 22/8/1 0.161
rs10258482 15262 C.A CC/CA/AA 12/16/3 0.355
rs2109513 15275 T.C TT/TC/CC 1/8/22 0.161
ss550827880 15927 A.T AA/AT/TT 27/4/0 0.048
rs56309428 15304 G.T GG/GT/TT 29/1/1 0.065
rs6466578 16036 C.T CC/CT/TT 1/8/22 0.161
rs10262524 16119 C.A CC/CA/AA 12/15/4 0.371
rs6466579 16322 T.C TT/TC/CC 13/12/6 0.387
rs10281637 16505 T.C TT/TC/CC 12/15/4 0.371
MAF – minimum allele frequency
*SNPs previously confirmed in a European population with MAF.5%
doi:10.1371/journal.pone.0063358.t004
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the challenges inherent in genotyping CAV2 variants. This study
also demonstrates the necessity of ensuring correct sequence
alignment and confirmation of variants from high throughput
sequencing to ensure the validity of results.
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